InteRNA Technologies BV

InteRNA Technologies aspires to improve cancer therapy effectiveness through innovative, intelligent miRNA-based therapeutics. InteRNA is a Dutch biotechnology company specializing in the development of RNA therapeutics for the treatment of cancer. InteRNA is a true pioneer in the discovery and creation of a new class of drugs, called microRNAs (miRNAs). Our proprietary technology platform has been developed for discovery and validation of miRNA-based drug candidates for the simultaneous regulation of multiple targets. With this approach, we address the need for novel therapeutics with higher efficacy and less drug resistance that really benefit patients. miRNAs and cancer Cancer is a disease caused by multiple defects in a cell. Drugs blocking multiple tumorigenic pathways may result in novel and better treatment strategies. MiRNAs can inhibit multiple downstream targets in a coordinated fashion. By optimally using this characteristic of miRNAs, InteRNA designs breakthrough therapies for cancer patients. miRNA identification & validation platform InteRNA created the core of its miRNA identification & validation platform through the use of massively parallel sequencing and proprietary, highly advanced bioinformatics methods to analyze, predict and validate miRNA sequences. Products InteRNA is building a diversified pipeline with a focus on two product development programs followed by two earlier stage programs. We aim to develop our two lead products INT-5A2 and INT-1B3 for treatment of patients with liver cancer (hepatocellular carcinoma, HCC) and skin cancer (melanoma). In addition, trailing programs encompass miRNA drug candidates for head and neck cancer (HNSCC) and epithelial cancers (pancreas, prostate, bladder). Source of foundation: Spin-off from Hubrecht Institute, Utrecht, NL For further information, see www.interna-technologies.com